Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN): Study protocol for a randomised controlled trial
Show others and affiliations
2017 (English)In: Trials, ISSN 1745-6215, E-ISSN 1745-6215, Vol. 18, no 1, article id 547Article in journal (Refereed) Published
Abstract [en]

Background: An abdominal aortic aneurysm (AAA) is a focal dilation of the abdominal aorta and is associated with a risk of fatal rupture. Experimental studies suggest that myo-inositol may exert beneficial effects on AAAs through favourable changes to biological pathways implicated in AAA pathology. The aim of the Inositol in the MAnaGemENt of abdominal aortic aneurysm (IMAGEN) trial is to assess if myo-inositol will reduce AAA growth. Methods/design: IMAGEN is a multi-centre, prospective, parallel-group, randomised, double-blind, placebo-controlled trial. A total of 164 participants with an AAA measuring ≥ 30 mm will be randomised to either 2 g of myo-inositol or identical placebo twice daily for 12 months. The primary outcome measure will be AAA growth estimated by increase in total infrarenal aortic volume measured on computed tomographic scans. Secondary outcome measures will include AAA diameter assessed by computed tomography and ultrasound, AAA peak wall stress and peak wall rupture index, serum lipids, circulating AAA biomarkers, circulating RNAs and health-related quality of life. All analysis will be based on the intention-to-treat principle at the time of randomisation. All patients who meet the eligibility criteria, provide written informed consent and are enrolled in the study will be included in the primary analysis, regardless of adherence to dietary allocation. Discussion: Currently, there is no known medical therapy to limit AAA progression. The IMAGEN trial will be the first randomised trial, to our knowledge, to assess the value of myo-inositol in limiting AAA growth.

Place, publisher, year, edition, pages
BioMed Central Ltd. , 2017. Vol. 18, no 1, article id 547
Keywords [en]
Abdominal aortic aneurysm, Clinical trial, Inositol, lipid, placebo, adult, Article, computer assisted tomography, controlled study, diet supplementation, double blind procedure, human, intention to treat analysis, lipid blood level, major clinical study, multicenter study, parallel design, patient compliance, prospective study, quality of life, randomized controlled trial, treatment outcome
National Category
Physiotherapy
Identifiers
URN: urn:nbn:se:kth:diva-227143DOI: 10.1186/s13063-017-2304-xScopus ID: 2-s2.0-85034117324OAI: oai:DiVA.org:kth-227143DiVA, id: diva2:1202986
Note

QC 20180502

Available from: 2018-05-02 Created: 2018-05-02 Last updated: 2018-05-02Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textScopus

Authority records BETA

Gasser, T. Christian

Search in DiVA

By author/editor
Gasser, T. Christian
By organisation
Solid Mechanics (Dept.)
In the same journal
Trials
Physiotherapy

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf